. 2011 Mar;7(3):154–162.

Table 2.

Summary of Phase II Clinical Trials with NS3A/4B Protease Inhibitors Telaprevir and Boceprevir

Trial	Patient characteristics	Treatment regimen	SVR (%)	RVR (%)	Relapse (%)
SPRINT-1 (boceprevir)	520 HCV genotype 1, treatment naïve	PRB28	54	39	30
		PRB48	67	37	7
		PR4/PRB24	56	60	24
		PR4/PRB44	75	64	3
		PR48	38	8	24
		PRB48 (standard dose)	67	37	7
		PRB48 (low dose)	36	25	22
PROVE 1 (telaprevir)	250 HCV genotype 1, treatment naïve	T12PR12	35	59	33
		T12PR24	61	81	2
		T12PR48	67	81	6
		PR48	41	11	23
PROVE 2 (telaprevir)	323 HCV genotype 1, treatment naïve	T12P12	36	50	48
		T12PR12	60	80	30
		T12PR24	69	69	14
		PR48	46	13	22
PROVE 3 (telaprevir)	453 HCV genotype 1, all patients (treatment failure/relapse)	T12PR24	51	61	30
		T24PR48	54	50	13
		T24P24	24	47	53
		PR48	14	0	53
	Prior treatment failure alone	T12PR24	39		37
		T24PR48	38		4
		T24P24	11		68
		PR48	9		40
	Prior relapse alone	T12PR24	69		18
		T24PR48	76		0
		T24P24	42		46
		PR48	20		62